

AMENDMENT

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Currently amended) A method of inhibiting infection of a cell by a virus in a patient comprising the step of administering to said patient an inhibitor of HMG-CoA reductase, wherein said virus is selected from the group consisting of human respiratory syncytial virus (RSV), parainfluenza virus, ebola virus, measles, canine distemper, Newcastle's Disease virus, bovine RSV, ovine RSV and turkey rhinotracheitis.
2. (Canceled)
3. (Currently amended) The method of claim [[2]]1, wherein said patient is or will become immunosuppressed.
4. (Previously presented) The method of claim 3, wherein said patient suffers from severe combined immunodeficiency.
5. (Previously presented) The method of claim 3, wherein said patient is taking or will take immunosuppressive drugs.
6. (Previously presented) The method of claim 5, wherein said patient is or will be a transplant recipient.
7. (Previously presented) The method of claim 1, wherein said patient has an existing viral infection.
8. (Canceled)
9. (Previously presented) The method of claim 1, wherein said patient is a human.

10. (Canceled)
11. (Original) The method of claim 9, wherein said virus is respiratory syncytial virus.
12. (Canceled)
13. (Original) The method of claim 1, wherein said inhibitor is selected from the group consisting of lovastatin, simvastatin, fluvastatin, atorvastatin, pravastatin and mevastatin.
14. (Previously presented) The method of claim 1, further comprising administering to said patient an inhibitor of isoprenylation that is distinct from said HMG-CoA reductase inhibitor.
15. (Previously presented) The method of claim 10, further comprising administering to said patient a nucleoside analog composition.
16. (Previously presented) The method of claim 15, further comprising administering to said patient a protease inhibitor.
17. (Previously presented) The method of claim 11, further comprising administering to said patient an antibody composition that binding immunologically to RSV.
18. (Previously presented) The method of claim 11, further comprising administering to said patient ribavarin.
19. (Previously presented) The method of claim 1, wherein said patient is a non-human mammal.
20. (Original) The method of claim 19, wherein said non-human mammal is a livestock animal.

21-50. (Canceled)